Medical Research and Beneficiaries
T.E.A.L.® Three Internal Programs
1.Educate communities about the signs, symptoms and risk factors of ovarian cancer in order to facilitate early detection of this deadly disease and save lives.
2. Provide support and resources to those touched by ovarian cancer including survivors, patients, caregivers and families.
3. Aid in the advancement of scientific research for ovarian cancer.
View Tell Every Amazing Lady®’s mission here.
Medical Research Beneficiaries
T.E.A.L.® has funded research at some of the countries most prestigious hospitals and institutions. View this interactive map to learn more. Apply to become a medical beneficiary by filling out this RFP application.
Accepting Proposals: March to May
DEADLINE to submit all proposals: MAY 31, 2020 (5/31/20)
All Grant Proposals will receive a response in November.
Johns Hopkins University
In 2013 T.E.A.L.® funded a $25,000 grant at Johns Hopkins University that focuses on the Characterization of the Genomic Profile of BRCA Negative Hereditary Breast and Ovarian Cancer, a study being conducted by Dr. Kara Long.
In 2017, T.E.A.L.® funded a $10,000 grant at Johns Hopkins University for a research study that focuses on developing a microfluidic DNA methylation assessment platform to identify epigenetic alterations present in early precursor lesions that can be exploited as biomarkers for early noninvasive detection of ovarian cancer.
The University Of Washington
T.E.A.L.® funded a research grant in 2012 and 2013 totaling $40,000 to evaluate the effectiveness of a triple screen for Ovarian Cancer. This is a two and a half year study headed by Dr. Barbara Goff at The University Of Washington.
Stand Up To Cancer’s Ovarian Cancer Dream Team through OCNA
In 2014, T.E.A.L.® showed their support of the Stand Up To Cancer Dream Team by donating $5000 to OCNA. The dream team is a Collaboration of Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition.
Massachusetts General Hospital
In 2014, T.E.A.L.® supported a research study at Massachusetts General Hospital for $30,000 called Identifying a genomic signature that predicts for recurrence in early stage ovarian cancers.
University of Penn School of Veterinary Medicine /Abramson Cancer Center/ PennVet Working Dog Center
In 2014, T.E.A.L.® helped fund studies at PennVet Working Center in which dogs are being trained to perform odor detection in human samples from patients with both malignant and benign ovarian cancer. They are achieving a 90% accuracy in identifying cancer plasma vs. normal. $5000 was donated towards this work from T.E.A.L.®
Memorial Sloan Kettering Cancer Center
In 2014, T.E.A.L.® funded a $20,000 study on the mutation landscapes of invasive mucinous ovarian carcinomas.
In 2018, Tell Every Amazing Lady® funded a $9350 survey research study that identified gaps in New Yorkers ovarian cancer knowledge. Memorial Sloan Kettering Section for the Treatment of Ovarian Cancer affectionately known as “Team Ovary: partnered with Tell Every Amazing Lady® to survey New York State residents and determine what knowledge gaps, if any, exist.
In 2009 T.E.A.L.® gave OCRF $50,000 to fund research by Dr. Tsz-Lun Yeung a postdoctoral fellow at the University of Texas MD Anderson Cancer Center. Dr. Yeung is researching new therapies to fight Ovarian Cancer.
In 2010 T.E.A.L.® gave OCRF $55,000 to fund research by Dr. Lin Zhang at the University of Pennsylvania School of Medicine. Dr. Zhang is researching new therapies for Ovarian Cancer using targeted microRNA.
In 2011 T.E.A.L.® gave OCRF $75,000 to fund research by Dr. See-Hyong Park a postdoctoral scholar at the Stanford University School of Medicine. Dr. Park is researching novel therapies for Ovarian Cancers that utilize PARP inhibitors.
In 2012 T.E.A.L.® donated $55,000 to support an OCRF research grant at John Hopkins University School of Medicine guided by Bin Guan. The study is based on functional characterization of the Tumor Suppressor ARID1A in Ovarian Cancer.
In 2013 T.E.A.L.® donated $25,000 to support an OCRF research grant at the Dana-Farber CancerInstitute. The research focuses on improving treatments for Ovarian Cancer by investigating ErbB3 as a Novel Therapeutic Target.
In 2014 T.E.A.L.® donated $30,000 to help fund a study at Weill Medical College of Cornell University led by Juan Cubillos-Ruiz in which ER Stress Sensor XBP1 as a key regulator of Ovarian Cancer immunity will be studied.
In 2015 T.E.A.L.® gave OCRF $20,000 to fund research by Dr. Jessica Chacon at the University of Pennsylvania. This study will be investigating the role of immunosuppressive molecules in Ovarian Cancer.
Following the merger between OCRF and OCNA in 2016, T.E.A.L.® gave OCRFA $7,500 to continue partially funding the research study by Dr. Jessica Chacon at the University of Pennsylvaniathat T.E.A.L.® previously funded in 2015.
In 2017, T.E.A.L.® awarded OCRFA $20,000 to fund research by Dr. Venkatesh Krishnan of Stanford University. This project, called Role of CCL15/CCR1 Axis in Ovarian Cancer Colonization of Omentum, will be investigating how the omental microenvironment contributes to the development of high-grade serous carcinoma (HGSC).
In 2018, since T.E.A.L.® is a Community Partner of OCRA, T.E.A.L.® will be a Collaborative Partner in Science collaborating with other organizations in funding a research study.
In 2015, T.E.A.L.® donated $10,000 to medical research for a BRCA Screening Program for Jewish Genetic Health.
University of Illinois at Chicago
In 2015, T.E.A.L.® funded a $20,000 research study at University of Illinois at Chicago that is working to determine if re-expression of PAX2 protein in cancer cells can be utilized to reverse or stop cancer progression.
In 2016, T.E.A.L.® funded a $20,000 research study at University of Illinois at Chicago that is attempting to identify the markers of cancer initiation and progression that are altered upon the loss of the tumor suppressor PTEN in fallopian tube epithelium (FTE).
In 2017, T.E.A.L.® funded a $35,000 research study at University of Illinois at Chicago that aims to test a new combination of drugs to prevent formation of metastatic lesions, reduce growth of metastatic tumors, and extend lives.
Icahn School of Medicine at Mount Sinai
In 2015, T.E.A.L.® helped fund a study at Icahn School of Medicine at Mount Sinai that is aimed at increasing survival and quality of life in women with ovarian cancer by developing new “personalized” biomarkers, replacing CA125 and CT scanning. $30,000 was donated towards this work from T.E.A.L.®
University of Kansas Cancer Center
In 2016, T.E.A.L.® partially funded a study at University of Kansas Cancer Center on Inhibiting Essential Functions of Cells to Treat Ovarian Cancer. $32,500 was donated towards this work from T.E.A.L.®.
Ovarian Cancer Institute Laboratory at Georgia Institute of Technology
In 2016, T.E.A.L.® partially funded a study at the Ovarian Cancer Institute Laboratory at Georgia Institute of Technology that is working to validate a metabolic diagnostic test for Ovarian Cancer. $10,000 was donated towards this work from T.E.A.L.®.
In 2018, T.E.A.L.® funded a $25,000 study, conducted by Dr. John McDonald at the Ovarian Cancer Institute, that is focusing on validating an early diagnostic test. Omic-level analyses combined with machine learning algorithms are emerging as a powerful approach to both ovarian cancer diagnostics and precision therapeutics. The long-term goal of this collaborative research project is the clinical implementation of highly accurate metabolomic-based biomarkers to detect early stage serous ovarian cancer ( and to distinguish between less aggressive and highly aggressive) sub- classes of the disease.
University of Notre Dame
In 2019, Tell Every Amazing Lady® fully funded a study at the University of Notre Dame called Characterizing CA125-antibody interactions using proteomics. Learn more about this study here. $25,000 was donated towards this work from T.E.A.L.®. Funds for this study were made possible by donations to the T.E.A.L.® Jane Fund.
Cedars Sinai Medical Center
In 2019, Tell Every Amazing Lady® partially funded a study at Cedars Sinai Medical Center called CRISPR/Cas9 screen to identify synthetic lethal targets in genetically engineered preneoplastic models of high grade serous ovarian cancer. $5,000 was donated towards this work from T.E.A.L.®.
In 2019, Tell Every Amazing Lady® partially funded a study at Cedars Sinai Medical Center called combining epidemioligic and genetic risk to provide accurate and accessible comprehensive risk prediction for the prevention of ovarian cancer. $14,000 was donated towards this work from T.E.A.L.®.
Awareness and Education Beneficiaries
Foundation for Women’s Cancer
Formerly known as Gynecologic Cancer Foundation In 2011 the Foundation for Women’s Cancer received $5,000 from T.E.A.L.® to provide Ovarian Cancer awareness through their programs.
In 2012 Tell Every Amazing Lady® became a $5,000 sponsor to help fund an Ovarian Cancer survivor course which will take place in New York in 2013.
In 2014, T.E.A.L.® donated $5,000 in support of FWC’s survivor education programs.
In 2015, T.E.A.L.® donated $15,000 in support of an Ovarian Cancer Survivor Course taking place in NYC in 2016.
In 2016, T.E.A.L.® donated $15,000 in support of an Ovarian Cancer Survivor Course taking place in NYC in 2018.
NOCC National Ovarian Cancer Coalition
In 2010 NOCC received $2,000 from T.E.A.L.® to provide awareness and education about Ovarian Cancer.
In 2013 T.E.A.L.® donated $3,500 to help fund Share’s Ovarian Cancer awareness and support services.
In 2014, T.E.A.L.® donated $5,000 to support Share’s survivor programs.
In 2015, T.E.A.L.® donated $5,000 to support Share’s Ovarian Cancer helpline where callers have the opportunity to speak with a cancer survivor or caregiver to answer questions, discuss treatment options, and aid in making informed decisions. Callers are connected with a peer whose situation is similar to their own or someone to simply listen.
In 2016, T.E.A.L.® donated $5,000 and continued to support Share’s Ovarian Cancer helpline where callers have the opportunity to speak with a cancer survivor or caregiver to answer questions, discuss treatment options, and aid in making informed decisions.
In 2017, Share received a $5,000 donation from T.E.A.L.® in support of Share’s Ovarian Cancer helpline. This helpline allows callers to speak with cancer survivors or caregivers to answer any questions they may have, including questions about treatment options. Yet another amazing resource T.E.A.L.® is glad to continue to support and be a part of.
In 2018, T.E.A.L.® pledged to donate a $5,000 over a 2 year span for collaborative programming with Share.